Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Purpose: We studied BCR-ABL1 transcript levels in patients with chronic myeloid leukemia in chronic phase (CML-CP) at 3, 6, and 12 months after starting imatinib to identify molecular milestones that would predict for overall survival (OS) and other outcomes more reliably than serial marrow cytogene...

Descripción completa

Detalles Bibliográficos

Publicado en:	Journal of Clinical Oncology Vol. 30; no. 3; pp. 232 - 239
Autores principales:	Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, Clark RE, Apperley JF, Milojkovic D, Bua M, Pavlu J, Paliompeis C, Reid A, Rezvani K, Goldman JM, Foroni L, Marin, David, Ibrahim, Amr R, Lucas, Claire, Gerrard, Gareth
Formato:	research Journal Article
Publicado:	American Society of Clinical Oncology 1/20/2012
Acceso en línea:	Ver este registro en EBSCOhost